Description of Research Expertise:
breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology
Selected Publications:
Clark AS, McAndrew NP, Troxel A, Feldman M, Lal P, Rosen M, Burrell J, Redlinger C, Gallgher M, Bradbury AR, Domchek SM, Fox KR, O'Dwyer PJ, DeMichele, AM: Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in
Advanced Breast Cancer Clinical Cancer Research Epub ahead of print : 2019.
Demissei BG, Finkelman B, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury A, Carver JR, Upshaw J, Armenian SH, Liu P, Ky B: Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy Cancer In press : 2019.
Lynch HF, Largent EA, Joffe S, DeMichele AM: Protecting clinical trial
participants and study integrity in the age of social media Cancer 124 (24): 4610-4617,2018.
Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas, JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH: A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with
metastatic solid tumours British Journal of Cancer 119 (10): 2018.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall, K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M: Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer New England Journal of Medicine 379 (20): 2018.
Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda, N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH: Predictors of prolonged benefit from palbociclib plus fulvestrant in women with
endocrine-resistant hormone receptor-positive/human epidermal growth factor
receptor 2-negative metastatic breast cancer in PALOMA-3 European Journal of Cancer 104 : 21-31,2018.
O'Shaughnessy Joyce, DeMichele Angela, Ma Cynthia X, Richards Paul, Yardley Denise A, Wright Gail Shaw, Kalinsky Kevin, Steis Ronald, Diab Sami, Kennealey Gerard, Geschwindt Ryan, Jiang Wei, Rugo Hope S: A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast cancer research and treatment 170 (3): 547-557,2018.
Banerjee Sagarika, Tian Tian, Wei Zhi, Shih Natalie, Feldman Michael D, Peck Kristen N, DeMichele Angela M, Alwine James C, Robertson Erle S: Distinct Microbial Signatures Associated With Different Breast Cancer Types. Frontiers in microbiology 9 : 951,2018.
Turner, N. C., Finn, R. S., Martin, M., Im, S. A., DeMichele, A., Ettl, J., Dieras, V., Moulder, S., Lipatov, O., Colleoni, M., Cristofanilli, M., Lu, D. R., Mori, A., Giorgetti, C., Iyer, S., Bartlett, C. H., Gelmon, K. A.: Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases Ann Oncol 29 (3): 669-680,2018.
Sturgeon, K. M., Hackley, R., Fornash, A., Dean, L. T., Laudermilk, M., Brown, J. C., Sarwer, D. B., DeMichele, A. M., Troxel, A. B., Schmitz, K. H.: Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema Cancer 124 (1): 95-104,2018.